Myelodysplastic/myeloproliferative neoplasm
MONDO:0006311A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.
Also known as: MDS-MPD, MDS/MPD, myelodysplastic myeloproliferative disease, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative diseases, myelodysplastic/myeloproliferative disorder, myelodysplastic/myeloproliferative disorders, myeloproliferative/myelodysplastic disorders
3282 clinical trials for this condition and its sub-types, 81 tagged with Myelodysplastic/myeloproliferative neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myelodysplastic/myeloproliferative neoplasm
-
Chronic myelomonocytic leukemia 167 trials · 187 incl. sub-types
1 sub-type
- Juvenile myelomonocytic leukemia 24 trials
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control Stopped earlyThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control Stopped earlyThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused Stopped earlyThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC